Judith Kelleher Anderson, FounderJudith Kelleher-Andersson, Ph.D.
Founder, President and Chief Executive Officer (CEO)

"A therapy that is only neuroprotective will never be sufficient to halt or reverse  neurodegenerative disease progression." I came to this realization after working in the neuroscience field for over 20 years as a graduate student, as a post-graduate fellow and after working at three biotech companies, where I directed the discovery of therapeutics aimed at Alzheimer's disease and other neurodegenerative disorders. MORE



Neuronascent, Inc. has discovered and is developing disease-modifying therapeutics for some of the most difficult to treat brain disorders that include Alzheimer's disease, Parkinson's disease and Down syndrome. 

Our lead candidate for Alzheimer's and potentially Parkinson's disease, NNI-362,  not only shows efficacy, by increasing the number of new neurons that survive to maturity that is associated with a reversal in behavioral  impairment, but is also shown to be safe in all FDA required GLP safety tests. This "neuron-regenerative" agent crosses into brain, following oral administration and increases the number of new neurons through a unique mechanism-of-action, suggesting a first-in-class therapeutic aimed at reversing Alzheimer's disease.



Feb 2016 Neuronascent's Research Tool Aimed at Stroke Tolerance is Characterized in 2016 Publication. The title of the article is “Arctic ground squirrel neuronal progenitor cells resist oxygen and glucose deprivation-induced death,” authored by the Founder and colleagues. READ MORE

Apr 2015 Neuronascent Secures Financing for Development of Its Alzheimer's Therapeutic. VIEW PRESS RELEASE

Feb 2015  Neuronascent Announces Expanded Patent Coverage In US and Russia For Its Alzheimer's Disease and Down Syndrome Therapeutics. VIEW PRESS RELEASE



» Home
» News & Events
» Contact Us
Management Team
Directors & Advisors
Drug Discovery
Intellectual Property
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Down Syndrome
Hibernation and Ischemia
© 2016 NeuroNascent, Inc. - All Rights Reserved - Website by TeraMark
This website contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “will,” “expects,” and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this site and involve risks and uncertainties that could cause actual results to differ materially from current expectations.